In May 2009, the plaintiffs in the currently filed Reglan lawsuits sought to consolidate their claims through Multidistrict Litigation (MDL), however the MDL panel issued an order denying the request. This denial of a Reglan MDL simply means that any Reglan lawsuits must proceed as individual lawsuits, which will not be formally coordinated.
Background on Reglan Litigation
Reglan and its generic (metoclopramide) has been linked to a rare neurological disease called tardive dyskinesia. Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs, including Reglan and metoclopramide. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by coordinated, constant movements of the mouth, tongue, jaw, and cheeks.